March 23, 2021
Renovacor, Inc. (Renovacor), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene dysfunction, and Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) (CHAQ), a special purpose acquisition company, sponsored by affiliates of Chardan Capital Markets (Chardan), have announced they have entered into a definitive business combination agreement. Upon closing of the transaction, CHAQ will be renamed Renovacor, Inc. and its common stock is expected to be listed on NYSE under the ticker symbol “RCOR”.
Latham & Watkins represents Chardan Healthcare Acquisition 2 Corp. in the transaction with a corporate deal team led by Houston partner Ryan Maierson and Orange County/New York partner Charles Ruck, with Orange County associates Brett Urig, Shannon Cheng, Jack Vanderford, and Trevor Yedoni and Houston associates Drew West and Danielle Kinchen. Advice was also provided on tax matters by New York partner Lisa Watts, with New York associate Alan Kimball; on benefits and compensation matters by Los Angeles partner Michelle Carpenter, with Los Angeles associate Harrison Taylor; on intellectual property litigation matters by Washington, D.C. partner Adam Perlman, with New York associate Michelle Ernst; on intellectual property matters by Washington, D.C. associate Morgan Brubaker; on healthcare regulatory matters by Washington, D.C. partner Stuart Kurlander and Bay Area counsel Betty Pang, with Washington, D.C. Alyssa Lattner; and on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards.